Zejula (niraparib) — United Healthcare
BRCA-2 altered uterine leiomyosarcoma (LMS)
Initial criteria
- Diagnosis of BRCA-2 altered uterine leiomyosarcoma (LMS)
- Disease is advanced, recurrent/metastatic, or inoperable
- Used as second-line or subsequent therapy
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Zejula therapy
Approval duration
12 months